The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction
Purpose of Review
To discuss the current evidence regarding the role of statins in heart failure with preserved ejection fraction (HFpEF).
HFpEF is a heterogeneous clinical syndrome with numerous contributors to its pathophysiology, including inflammation, arterial stiffness, and dysfunction of the autonomic nervous system. The management of HFpEF is currently symptomatic whereas agents that improve the survival of patients with HF with reduced ejection fraction, including beta-blockers, inhibitors of renin angiotensin system, and aldosterone antagonists have showed no effect on the outcome of HFpEF. On the other hand, preliminary data suggest that statins might reduce the risk of hospitalization and improve the survival of patients with HFpEF. The pleiotropic actions of these agents, particularly their effects on left ventricular function and structure and their antiinflammatory and vasoprotective actions, appear to be implicated in the improved survival of patients with HFpEF treated with statins.
Given the rising prevalence of HFpEF and the lack of treatments that affect the cardiovascular morbidity and mortality of this population, these apparent benefits of statins have potentially important clinical implication. However, randomized controlled trials are clearly needed to establish the role of statins in the management of HFpEF.
KeywordsStatins Heart failure with preserved ejection fraction Mortality Pleiotropic actions Left ventricular remodeling
Compliance with ethical standards
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360:7–22.Google Scholar
- 10.Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383–9.Google Scholar
- 19.Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ, National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Med J Aust. 2011;194:405–9.Google Scholar
- 20.Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240–327.Google Scholar
- 21.National Vasc Dis Prev Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012.Google Scholar
- 24.European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.CrossRefGoogle Scholar
- 29.Røe ÅT, Sjaastad I, Louch WE. Heart failure with preserved ejection fraction. Tidsskr Nor Legeforen. 2017;137(18).Google Scholar
- 30.• Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200 The most recent European guidelines for the management of patients with heart failure. CrossRefGoogle Scholar
- 34.•• Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol. 2014;113:1198–204 A recent meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. CrossRefGoogle Scholar
- 53.Verloop WL, Beeftink MMA, Santema BT, Bots ML, Blankestijn PJ, Cramer MJ, et al. A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction. PLoS One. 2015;10:1–14.Google Scholar